重复玻璃体内注射雷珠单抗治疗糖尿病性黄斑水肿  

Consecutive intravitreal injection of Lucentis for the treatment of diabetic macular edema

作　　者：李秀娟[1] 

机构地区：[1]郑州大学第一附属医院眼科,450052

出　　处：《中华眼外伤职业眼病杂志》2013年第12期887-889,共3页Chinese Journal of Ocular Trauma and Occupational Eye Disease

摘　　要：目的观察重复玻璃体内注射雷珠单抗（Lucentis）治疗糖尿病性黄斑水肿（DME）的临床疗效。方法56例（76只眼），经眼底检查、荧光素眼底血管造影（FFA）、光学相干断层扫描（OCT）确诊为DME。年龄为27—73岁，平均（54．97±7．70）岁。治疗前logMAR最佳矫正视力（BCVA）平均为1．01±0．43，黄斑中心厚度平均为（565．38±124．75）斗m。分别接受玻璃体内注射Lucentis0．5mg（0．05m1）2—5次，平均（3．55±1．20）次，每次间隔1个月左右。结果随访6～12个月，平均（8．79±2．53）个月，76只眼的平均logMAR最佳矫正视力为0．65±0．16，较治疗前提高（t=6．61，P=0．00）。其中65只眼（85．53％）的logMAR最佳矫正视力提高2行或以上。OCT示：黄斑中心厚度降低至（276．46±18．56）¨m（t=19，87，P=0．00）。治疗过程中未发现严重眼部或全身并发症。结论重复玻璃体内注射Lucentis治疗DME，能明显减轻血管渗漏及水肿程度，改善视力，未发现严重并发症。Objective To evaluate the efficiency of consecutive intravitreal injection of Lucentis for diabetic macular edema （DME）. Methods A prospective study included 76 eyes of 56 patients with DME which was diagnosed by examination of regular inspection, fundus fluorescein angiography （FFA） and optic coherence tomography （OCT）. The patients aged from 27 to 73 years old with a mean age of （54.97 ±7.70） years old. The best corrected visual acuity （BCVA） of log MAR was 1.01±0.43 and the mean central macular thickness （CMT） was （565.38 ±124.75）μm. The patients received consecutive intravitreous injection of 0.5mg （ 0.05 ml） Lucentis at 1 month interval. Results The follow - up period ranged from 6 to 12 months, mean（ 8.79±2.53 ） months. The mean log MAR BCVA of 76 eyes was significantly improved as 0.65 ±0.16, and the difference was statistically significant compared with before （t =6. 61 ,P =0.00）. The logMAR BCVA was improved in 65 eyes （85.53 % ）. The mean CMT was （276.46 ±18.56） μm in postinjection, showing a statistically significant improvement （t = 19. 87, P = 0.00 ）. No significant adverse events occurred. Conclusion Intravitreal injection of Lucentis therapy is well tolerated with a significant improvement in BCVA and decrease in CMT for patients with DME.

关 键 词：黄斑水肿 糖尿病性 雷珠单抗(Lucentis) 玻璃体内注射 重复 

分 类 号：R774.5[医药卫生—眼科] R587.1[医药卫生—临床医学]